Intellia Therapeutics

This clinical-stage biotechnology company, established in 2014, is known for its focus on the development of potentially curative therapeutics using CRISPR-based technologies. Based in Cambridge, MA, it is currently under the leadership of CEO John Leonard. The company's innovative approach to gene editing has positioned it as a significant player in the biotech industry.